Sep 15, 2020
GSK highlights scientific advances across its growing oncology portfolio at ESMO Virtual Congress 2020
Jun 16, 2020
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
May 21, 2020
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
Apr 29, 2020
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
Apr 06, 2020
UK companies team up to tackle coronavirus
Feb 26, 2020
Comprehensive Study of the Global Diabetes Market (2018-2024) Featuring Profiles of Key Players Abbott Labs, BD & Co, Eli Lilly & Co, GSK, NextCell Pharma, and More
Feb 24, 2020
U.S. FDA accepts GSK's sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
Feb 03, 2020
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Jan 21, 2020
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
Dec 30, 2019
Global Pediatric Medicines Market Review 2018-2019 & Forecast to 2024 with Profiles of Leading Players Abbott Laboratories, GlaxoSmithKline, Novartis, Sanofi, and Vertex Pharmaceuticals
Dec 16, 2019
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Sep 28, 2019
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
Aug 17, 2018
Respiratory Tract Infections Drug Development Pipeline Review 2018 Featuring Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline
Jun 20, 2018
TrialScope Selected by Leading Global Pharmaceutical Company to Support Clinical Trial Disclosure and Transparency
Dec 12, 2017
GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
Oct 25, 2017
CDC's Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up
Oct 20, 2017
Shingrix approved in the US for prevention of shingles in adults aged 50 and over
Sep 20, 2017
Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva
Sep 18, 2017
Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US
Sep 18, 2017
Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple)